Barnes, TR, Paton, C, Cavanagh, MR, Hancock, E, Taylor, DM (2007). A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophrenia Bulletin 33, 1397–1403.
Brown, S, Barraclough, B, Inskip, H (2000). Causes of the excess mortality of schizophrenia. British Journal of Psychiatry 177, 212–217.
Buckley, PF, Miller, DD, Singer, B, Arena, J, Stirewalt, EM (2005). Clinicians’ recognition of the metabolic adverse effects of antipsychotic medications. Schizophrenia Research 79, 281–288.
Chugh, SS, Jui, J, Gunson, K, Stecker, EC, John, BT, Thompson, B, Ilias, N, Vickers, C, Dogra, V, Daya, M, Kron, J, Zheng, ZJ, Mensah, G, McAnulty, J (2004). Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. Journal of the American College of Cardiology 44, 1268–1275.
Crump, C, Winkleby, MA, Sundquist, K, Sundquist, J (2013). Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. American Journal of Psychiatry 170, 324–333.
D'Amico, M, Agozzino, E, Biagino, A, Simonetti, A, Marinelli, P (1999). Ill-defined and multiple causes on death certificates – a study of misclassification in mortality statistics. European Journal of Epidemiology 15, 141–148.
Deuschle, M, Paul, F, Brosz, M, Bergemann, N, Franz, M, Kammerer-Ciernioch, J, Lautenschlager, M, Lederbogen, F, Roesch-Ely, D, Weisbrod, M, Kahl, KG, Reichmann, J, Gross, J, Umbreit, J (2013). Assessment of cardiovascular disease risk in patients with schizophrenia spectrum disorders in German psychiatric hospitals: results of the pharmacoepidemiologic CATS study. Social Psychiatry and Psychiatric Epidemiology 48, 1283–1288.
Docherty, M, Stubbs, B, Gaughran, F (2016). Strategies to deal with comorbid physical illness in psychosis. Epidemiology and Psychiatric Sciences 25, 197–204.
Fan, Z, Wu, Y, Shen, J, Ji, T, Zhan, R (2013). Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. Journal of Psychiatric Research 47, 1549–1556.
Frome, EL (1983). The analysis of rates using Poisson regression models. Biometrics 39, 665–674.
Gardner-Sood, P, Lally, J, Smith, S, Atakan, Z, Ismail, K, Greenwood, KE, Keen, A, O'Brien, C, Onagbesan, O, Fung, C, Papanastasiou, E, Eberhard, J, Patel, A, Ohlsen, R, Stahl, D, David, A, Hopkins, D, Murray, RM, Gaughran, F, IMPaCT team (2015). Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT randomized controlled trial. Psychological Medicine 45, 2619–2629.
Gutiérrez-Rojas, L, Pulido, S, Azanza, JR, Bernardo, M, Rojo, L, Mesa, FJ, Martínez-Ortega, JM (2016). Risk factor assessment and counselling for 12 months reduces metabolic and cardiovascular risk in overweight or obese patients with schizophrenia spectrum disorders: the CRESSOB study. Actas Españolas de Psiquiatría 44, 20–29.
Khasawneh, FT, Shankar, GS (2014). Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia. Cardiology Research and Practice 2014, 273060.
Laursen, TM, Wahlbeck, K, Hällgren, J, Westman, J, Ösby, U, Alinaghizadeh, H, Gissler, M, Nordentoft, M (2013). Life Expectancy and Death by Diseases of the Circulatory System in Patients with Bipolar Disorder or Schizophrenia in the Nordic Countries. PLoS One 8, e67133.
Mackin, P, Bishop, D, Watkinson, HM, Ferrier, IN (2008). A prospective study of glycaemic status in anti-psychotic-treated patients. Journal of Psychopharmacology 22, 563–566.
Mitchell, AJ, Delaffon, V, Vancampfort, D, Correll, CU, De Hert, M (2012). Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychological Medicine, 125–147.
Morrato, EH, Newcomer, JW, Allen, RR, Valuck, RJ (2008). Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. Journal of Clinical Psychiatry 69, 316–322.
Newcomer, JW, Haupt, DW (2006). The metabolic effects of antipsychotic medications. Canadian Journal of Psychiatry 51, 480–491.
Nordentoft, M, Wahlbeck, K, Hällgren, J, Westman, J, Osby, U, Alinaghizadeh, H, Gissler, M, Laursen, TM (2013). Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS ONE 8, e55176.
Olsson, E, Westman, J, Sudic Hukic, D, Eriksson, SV, Edman, G, Bodén, R, Jedenius, E, Reutfors, J, Berntsson, A, Hilding, A, Schalling, M, Östenson, CG, Ösby, U (2015). Diabetes and glucose disturbances in patients with psychosis in Sweden. BMJ Open Diabetes Research and Care 3, e000120.
Osby, U, Correia, N, Brandt, L, Ekbom, A, Sparén, P (2000). Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophrenia Research 45, 21–28.
Ösby, U, Westman, J, Hällgren, J, Gissler, M (2016). Mortality trends in cardiovascular causes in schizophrenia, bipolar and unipolar mood disorder in Sweden 1987–2010. European Journal of Public Health 26, 867–871.
Ray, WA, Chung, CP, Murray, KT, Hall, K, Stein, CM (2009). Atypical antipsychotic drugs and the risk of sudden cardiac death. New England Journal of Medicine 360, 225–235.
Saha, S, Chant, D, McGrath, J (2007). A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Archives of General Psychiatry 64, 1123–1131.
Smith, DJ, Langan, J, McLean, G, Guthrie, B, Mercer, SW (2013). Schizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: cross-sectional study. BMJ Open 3, pii: e002808. doi: 10.1136/bmjopen-2013-002808.
Tiihonen, J, Lönnqvist, J, Wahlbeck, K, Klaukka, T, Niskanen, L, Tanskanen, A, Haukka, J (2009). 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374, 620–627.